CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-16 | ROBIN HOWARD W President & CEO | Sale | −20,361 | $0.72 | $15K | 939,797 |
| 2023-02-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −10,484 | $3.00 | $31K | 303,179 |
| 2023-02-16 | Wilson Mark Andrew Chief Legal Officer | Sale | −8,275 | $3.00 | $25K | 265,223 |
| 2023-02-16 | Thomsen Jillian B. Chief Financial Officer | Sale | −10,267 | $3.00 | $31K | 313,497 |
| 2023-02-16 | ROBIN HOWARD W President & CEO | Sale | −19,635 | $3.00 | $59K | 960,158 |
| 2022-11-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −13,460 | $3.57 | $48K | 313,663 |
| 2022-11-16 | Wilson Mark Andrew Chief Legal Officer | Sale | −8,690 | $3.57 | $31K | 272,498 |
| 2022-11-16 | Thomsen Jillian B. Chief Financial Officer | Sale | −11,095 | $3.57 | $40K | 323,764 |
| 2022-11-16 | ROBIN HOWARD W President & CEO | Sale | −38,014 | $3.57 | $136K | 979,793 |
| 2022-09-23 | Curet Myriam Director | Sale | −4,198 | $3.16 | $13K | 31,777 |
| 2022-09-23 | Ajer Jeffrey Robert Director | Sale | −4,198 | $3.16 | $13K | 38,512 |
| 2022-09-22 | CHESS ROBERT Director | Sale 10b5-1 | −10,200 | $0.67 | $7K | 274,773 |
| 2022-09-22 | CHESS ROBERT Director | Sale | −5,100 | $3.19 | $16K | 228,179 |
| 2022-09-16 | WHITFIELD ROY A Director | Grant or award | +10,200 | 246,250 | ||
| 2022-09-16 | WHITFIELD ROY A Director | Grant or award · Stock Option | +20,400 | 20,400 | ||
| 2022-09-16 | GREER R SCOTT Director | Grant or award | +10,200 | 303,574 | ||
| 2022-09-16 | GREER R SCOTT Director | Grant or award · Stock Option | +20,400 | 20,400 | ||
| 2022-09-16 | EASTHAM KARIN Director | Grant or award | +10,200 | 23,233 | ||
| 2022-09-16 | EASTHAM KARIN Director | Grant or award · Stock Option | +20,400 | 20,400 | ||
| 2022-09-16 | Curet Myriam Director | Grant or award | +10,200 | 35,975 |
Page 7 of 18 · 355 trades